News
UTHR
588.38
+1.36%
7.87
United Therapeutics CEO Martine Rothblatt disposes 9,500 shares for $5.49 million
PUBT · 2d ago
United Therapeutics CFO James Edgemond disposes of shares worth $5.2 million
PUBT · 2d ago
3 Reasons Investors Love United Therapeutics (UTHR)
Barchart · 3d ago
Top Executive Makes Notable Move With United Therapeutics Shares
TipRanks · 3d ago
United Therapeutics CEO Martine Rothblatt disposes of shares worth $10.97 million
PUBT · 3d ago
United Therapeutics EVP, General Counsel Paul Mahon sells 8,300 shares for $4.8 million
PUBT · 3d ago
How FDA RMAT Status For Bioengineered Liver Device At United Therapeutics (UTHR) Has Changed Its Investment Story
Simply Wall St · 4d ago
United Therapeutics CFO James Edgemond disposes of common shares worth $5,747,755.31
PUBT · 5d ago
United Therapeutics CEO Martine Rothblatt disposes common shares worth $5,378,572.62
PUBT · 6d ago
Weekly Report: what happened at UTHR last week (0406-0410)?
Weekly Report · 04/13 09:29
A Look At United Therapeutics (UTHR) Valuation After RMAT Win And Tyvaso Phase 3 Success
Simply Wall St · 04/12 11:19
United Therapeutics CEO Martine Rothblatt disposes of shares worth $5.45 million
Reuters · 04/10 20:33
United Therapeutics Is Maintained at Equal-Weight by Morgan Stanley
Dow Jones · 04/10 16:21
Morgan Stanley Maintains Equal-Weight on United Therapeutics, Raises Price Target to $519
Benzinga · 04/10 16:10
Is It Too Late To Consider United Therapeutics (UTHR) After A 106% One-Year Surge?
Simply Wall St · 04/10 14:26
Nike downgraded, IBM initiated: Wall Street’s top analyst calls
TipRanks · 04/10 13:42
United Therapeutics price target raised to $519 from $471 at Morgan Stanley
TipRanks · 04/10 12:57
Morgan Stanley Remains a Hold on United Therapeutics (UTHR)
TipRanks · 04/10 12:27
UNITED THERAPEUTICS CORP <UTHR.O>: RAYMOND JAMES INITIATES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $700
Reuters · 04/10 11:23
United Therapeutics initiated with an Outperform at Raymond James
TipRanks · 04/10 09:40
More
Webull provides a variety of real-time UTHR stock news. You can receive the latest news about United Therapeutics Corp. through multiple platforms. This information may help you make smarter investment decisions.
About UTHR
United Therapeutics Corporation is a pharmaceutical company. The Company markets and sells commercial therapies to treat pulmonary arterial hypertension (PAH): Tyvaso DPI (treprostinil) Inhalation Powder (Tyvaso DPI); Tyvaso (treprostinil) Inhalation Solution (nebulized Tyvaso), which includes the Tyvaso Inhalation System; Remodulin (treprostinil) Injection (Remodulin); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). Tyvaso DPI and nebulized Tyvaso are also approved to treat pulmonary hypertension associated with interstitial lung disease (PH-ILD). It also markets and sells an oncology product, Unituxin (dinutuximab) Injection for the treatment of high-risk neuroblastoma, and the Remunity Pump for Remodulin. Tyvaso DPI is a drug-device combination product that incorporates the dry powder formulation technology and Dreamboat inhalation device technology used in MannKind’s Afrezza (insulin human) Inhalation Powder product.